Stanford Blocks 15-PGDH to Regrow Cartilage in Mice, Aiming at 32.5 Million U.S. Osteoarthritis Cases
Updated
Updated · ScienceAlert · Aug 14
Stanford Blocks 15-PGDH to Regrow Cartilage in Mice, Aiming at 32.5 Million U.S. Osteoarthritis Cases
2 articles · Updated · ScienceAlert · Aug 14
Summary
Old mice regained thicker cartilage after Stanford researchers blocked the aging-linked enzyme 15-PGDH, while young mice avoided post-injury osteoarthritis after an ACL-tear model.
Human cartilage from knee-replacement patients showed the same direction of effect—stiffer tissue and less inflammation—suggesting the target may work beyond animal models.
The study found regeneration came from existing chondrocytes changing gene activity, not from stem cells, pointing to a different repair mechanism for adult cartilage.
A clinical trial is the next step, and researchers said a 15-PGDH blocker has already cleared an earlier human safety trial for muscle weakness, which could speed related testing.
The finding lands in a crowded osteoarthritis race: ARPA-H has committed more than $100 million to joint-regeneration programs, while other teams and semaglutide studies pursue separate repair pathways.
Could a single protein blocker eliminate the need for knee replacements by forcing your own cells to regrow lost cartilage?
If our bodies naturally suppress joint repair as we age, what hidden dangers might arise when we artificially switch that healing back on?
Regenerating Human Cartilage Without Stem Cells: The Stanford 15-PGDH Inhibitor Revolution
Overview
Stanford researchers discovered that blocking the aging enzyme 15-PGDH with a small molecule drug can reprogram old cartilage cells (chondrocytes) to behave like youthful, regenerative cells. In animal studies, this treatment caused worn knee cartilage to thicken and regenerate true, healthy hyaline cartilage, not just weaker scar tissue. After joint injuries, mice treated with the inhibitor showed less osteoarthritis and better mobility. When applied to diseased human cartilage in the lab, the therapy reduced tissue breakdown and triggered new cartilage growth. These findings suggest a promising, non-invasive way to restore joint health by directly reactivating the body’s own cells.